By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Repros Therapeutics Inc. 

2408 Timberloch Place
Suite B-7
The Woodlands  Texas  77380  U.S.A.
Phone: 281-719-3400 Fax: 281-719-3446


SEARCH JOBS








Company News
Repros Therapeutics Inc. (RPRX) Reports Second Quarter 2014 Financial Results 8/11/2014 7:51:03 AM
Repros Therapeutics Inc. (RPRX) Release: FDA Confirms Sperm And Testosterone Endpoints As Key Parameters For Assessment Of Androxal® Versus Approved Topical Gel And Placebo 7/16/2014 7:40:19 AM
Repros Therapeutics Inc. (RPRX) Fully Enrolls Second Previously Announced Head To Head Study Of Androxal® Versus The Leading Topical Testosterone Gel 5/13/2014 11:39:36 AM
Repros Therapeutics Inc. (RPRX) Reports First Quarter 2014 Financial Results 5/12/2014 9:04:45 AM
Repros Therapeutics Inc. (RPRX) Release: FDA Recommends Sperm Endpoints As Key Parameters For Assessment Of Androxal® Versus Approved Topical Gel 4/30/2014 5:15:02 PM
Repros Therapeutics Inc. (RPRX) Fully Enrolls First Of Two Previously Announced Head To Head Studies Of Androxal® Versus The Leading Topical Testosterone Gel 4/14/2014 9:14:57 AM
Repros Therapeutics Inc. (RPRX) Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex® In The Treatment Of Uterine Fibroids And Endometriosis 3/18/2014 8:57:38 AM
Repros Therapeutics Inc. (RPRX) Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex® In The Treatment Of Uterine Fibroids And Endometriosis 3/17/2014 9:10:37 AM
Repros Therapeutics Inc. (RPRX) Reports Fourth Quarter And Year End 2013 Financial Results 3/13/2014 8:51:02 AM
Repros Therapeutics Inc. (RPRX) Reports Findings From The Six Month Study Of Androxal® In Men With Secondary Hypogonadism 2/10/2014 9:24:02 AM
12345678910...
//-->